were to increase, among persons chronically infected with the hepatitis C (HCV) virus, attendance at specialist outpatient clinics and initiation on antiviral therapy. We evaluated progress towards these goals by comparing the odds, across time, of (a) first clinic attendance within 12 months of HCV diagnosis (n=9,747); and (b) initiation on antiviral treatment within 12 months of first attendance (n=5,736). Record-linkage between the national HCV diagnosis (1996 -2009 ) and HCV Clinical (1996 databases and logistic regression analyses were conducted for both outcomes. For outcome (a), 32% and 45% in the respective pre-Phase II (before 1 May 2008) and Phase II periods attended a specialist clinic within 12 months of diagnosis; the odds of attendance within 12 months increased over time (OR=1.05 per year, 95% CI: 1.04-1.07), but was not significantly greater for persons diagnosed with HCV in the Phase II era, compared with the pre-Phase II era (OR=1.1, 95% CI: 0.9-1.3), after adjustment for temporal trend. For outcome (b), 13% and 28% were initiated on treatment within 12 months of their first clinic attendance in the pre-Phase II and Phase II periods, respectively. Higher odds of treatment initiation were associated with first clinic attendance in the Phase II (OR=1.9, 95% CI: 1.5-2.4), compared with the pre-Phase II era. Results were consistent with a positive impact of the Hepatitis C Action Plan on the treatment of chronically-infected individuals, but further monitoring is required to confirm a sustained effect. SJ Hutchinson has served as a speaker for events sponsored by MSD, Gilead, Janssen, and Roche. S Allen has served as an advisory board member for Janssen-Cilag Ltd. R Fox has served as a speaker or an advisory board member for MSD, Janssen, Roche, and Boehringer-Ingelheim. A Fraser has served as a speaker for Gilead and as an advisory board member for MSD and Janssen. N Kennedy has served as a speaker, a consultant, and an advisory board member for Janssen, MSD and Gilead. PC Hayes has served as a speaker or as an advisory board member for, or has received research funding from Norgine, MSD, Jannsen, Gilead, Pfizer, Gore, Roche, ONO Pharmaceuticals, and Falk.
INTRODUCTION
Infection with the hepatitis C virus (HCV) is a serious public health problem worldwide, affecting 170 million people according to the WHO. The long natural history of chronic HCV infection means that the greatest burden -from life-threatening complications such as decompensated cirrhosis and hepatocellular carcinoma -is still to come. Modelling work to forecast the future burden indicates that unless identification, management, and treatment of chronic cases is vastly improved, the numbers of patients developing end-stage liver disease will continue to rise. (1) Challenges for chronic HCV patient management along the entire pathway from diagnosis to antiviral therapy have been identified; (2) (3) (4) and there is much reported variability in rates of attendance at specialist hepatitis clinics and treatment uptake. (5, 6) Previous research, with only a few exceptions, (7) has typically involved relatively small cohorts of HCV patients with limited follow-up; large population-based studies are needed for assessment of all aspects of HCV patient management, and for evaluation of national public health policy initiatives.
In recognition that HCV represents one of the most serious contemporary public health issues in Scotland, the Scottish Health Minister and Chief Medical Officer jointly launched million of government investment, were "to diagnose HCV-infected people, particularly those who would most benefit from treatment, and to ensure that those infected receive McDonald 4 optimal treatment, care and support". (8) A key action was "to develop clinical services to increase numbers of persons undergoing therapy in Scotland" (Action 6). The extent to which the Action Plan has succeeded in this regard has not yet been extensively evaluated, but preliminary data indicate that the annual number of persons starting antiviral therapy has more than doubled between 2007/2008 (n = 468) and 2010/2011 (n = 1049). (9) Therefore, the main goals of the current study were (a) to examine the rate of, and factors associated with, attendance at a HCV specialist clinic following HCV diagnosis among chronically infected patients in Scotland; and (b) to examine the rate of, and factors associated with, initiation on HCV antiviral therapy among chronically infected patients who have attended a HCV specialist treatment clinic in Scotland. In addition to the principal aims stated above, further goals of the Action Plan included: increasing the numbers in specialist [hepatitis C] care among people who inject drugs (PWID); "improving HCV testing and referral activities by General Practitioners (GPs) and other community setting practitioners" (Action 10), increasing the numbers referred from prison, and "promoting the treatment of HCV-infected inmates in prisons" (Action 7).(8) Thus, we also assessed the effect of the implementation of the Phase II Action Plan on attendance at specialist clinics, specifically within these groups.
METHODS

Data sources and linkage
The Scottish Hepatitis C Clinical Database, held at Health Protection Scotland (HPS), contains clinical follow-up data for HCV-infected patients attending specialist outpatient treatment clinics across Scotland (involving 16 clinics as at 2010; clinics were located in forename initial, and surname Soundex was required for a successful link (see Fig. 1 ).
Data analysis
Two principal analyses were conducted, with two outcome events defined accordingly to compare event rates in the periods before and after the launch of the HCV Action Plan: (a) The HB restriction was imposed because data on the HCV Clinical database was considered up-to-date (i.e. sufficiently complete to end 2010) for only the subset of specialist clinics located within the included HBs, at the time of analysis.
Logistic regression modelling was used to examine the association between the outcome 'first clinic attendance within 12 months of HCV diagnosis' (if person had attended multiple clinics, the earliest date) and the covariates sex, age at diagnosis (grouped into <20 years, 20-29, 30-39, 40-49, 50+ years), risk group (current/former PWID, non-PWID, not known), calendar period of HCV diagnosis (1996-1998, 1999-2001, 2002-2004, 2005-2007, 2008-2009) , source of HCV test referral (hospital, GP, drug/counselling clinic, prison, other), and HB (GG & C, other). The period 2002-2004 was chosen as reference period so odds ratios (ORs) for the periods immediately preceding and immediately following the launch of the Phase II Action Plan could be informally compared. After removing 107 persons whose date of death was recorded before or within 30 days following HCV diagnosis date and 392 persons whose date of HCV diagnosis occurred after their first clinical appointment, 9, 747 records remained for analysis. A sensitivity analysis was done to assess the influence of those cases where the date of first appointment was identical to the date of HCV diagnosis, but the date of HCV diagnosis was indicated to be more than 2 months earlier according to the Clinical database; for these cases, an earlier HCV diagnosis date may not have been identified due to the limited availability of identifiers for 12% of records on the HCV Diagnosis database (including those who tested anonymously at a genito-urinary medicine (GUM) clinic), or the individual may have been tested outwith Scotland.
Because any extra effect of the Action Plan needs to be distinguished from a linear temporal trend in the log odds of first clinic attendance, a further analysis was conducted in which the variable period of HCV diagnosis was replaced by date of HCV diagnosis, fitted as a linear covariate (coded as decimal years), and the binary covariate era was added, defined as HCV diagnosis occurring pre-Phase II Action Plan (before 1 May 2008) or Phase II Action Plan (1 May 2008 to 31 December 2010). Tests for interaction between era and risk group, and era and referral source were also conducted, and separate multifactorial regression analyses were conducted for four subgroups of interest: PWID, referrals from GP, drug/counselling clinics, and prison settings.
For analysis (b), the study population was restricted to linked chronic HCV-infected patients attending the following specialist clinics: Crosshouse Hospital, Dumfries & Galloway Royal Infirmary, Ninewells Hospital, Gartnavel General Hospital, Glasgow Royal Infirmary, Kirkcaldy Hospital, Monklands Hospital, Raigmore Hospital, Southern General Hospital, Stirling Royal Infirmary, and Edinburgh Western General in the period 1 January 1996 to 31 December 2009 (n = 5,786). The remaining clinics that contribute to the HCV Clinical database were excluded because data entry to end 2010 was either known to be incomplete or completeness could not be established.
After removing cases for whom the earliest date of initiation on antiviral therapy was recorded as occurring before the date of first clinic appointment (possibly because of being treated previously at a different clinic or moving to another HB area after treatment initiation; n = 46) and where date of death preceded first clinic appointment (n = 4; probable record-linkage errors), 5,736 records remained for analysis.
Logistic regression modelling was used to examine the association between the outcome 'initiation on antiviral therapy within 12 months of first clinic attendance and the covariates: sex, age at first clinic (<20, 20-29, 30-39, 40-49, 50+ years), risk group (current/former PWID, non-PWID, not known), calendar period of first clinic (1996-1998, 1999-2001, 2002-2004, 2005-2007, 2008-2009) , and genotype (1, 2/3, 4/5, not known). A random intercept for clinic was included to model the correlation structure of the data (variation in treatment initiation rates across clinics); approximate 95% confidence intervals were calculated by assuming a normally-distributed standard error (SE).
As done for outcome (a), a random-effects logistic regression analysis was conducted to ascertain if there was any extra effect of the Action Plan beyond a linear temporal trend in the log odds of treatment initiation within 12 months. In this analysis, the variable period of first clinic was replaced by date of first clinic (fitted as a linear covariate), and the binary covariate era, defined as first clinic appointment occurring pre-Phase II Action Plan (before 1 May 2008) or Phase II Action Plan (1 May 2008 to 31 December 2010). A test for interaction between risk group and era was also conducted.
We expressed the clinical relevance of any effect attributable to the initiation of the Phase II Action plan in both analysis (a) and (b), by reporting absolute effects. These absolute effects were estimated as follows. First, the expected number of patients achieving the outcome at a single selected time point (two years after the initiation of Phase II) was calculated from the predicted probabilities derived from the fitted adjusted logistic regression model (including the era covariate) by applying these probabilities to a hypothetical cohort of 100 persons. Second, the expected number of patients achieving the outcome at the same time point in the counterfactual situation (i.e., had the intervention not taken place) was calculated from predicted probabilities derived from the fitted adjusted logistic regression model, but with era set to 0, and the probabilities were applied to a 100person hypothetical cohort. In the counterfactual situation, the probability of an outcome was derived from the temporal trend and the other covariates only.
RESULTS
First clinic attendance: demographic characteristics
A detailed breakdown of the study population (n = 10,155; i.e., those persons diagnosed with chronic HCV infection 1996-2009, restricted set of HBs) according to key baseline characteristics is provided in Table 1 . The median age at diagnosis was 33 years; 70% of the study population (restricted by HB) was male, 57% was PWID, and a hospital setting was the most common referral source (32%) for HCV testing. Overall, 54% (5,469/10,155 persons) was determined to have ever attended a specialist clinic. The highest rates of everattendance at a specialist clinic were observed in males (56%), non-PWID (59%), those diagnosed in 1996-1998 (56%), and in referrals from a GP (61%).
Odds of first clinic attendance within 12 months of HCV diagnosis
Thirty-four per cent (3,286/9,747) of the eligible study population (i.e., persons diagnosed with chronic HCV in the period 1996-2009, who were alive at 30 days following date of diagnosis and whose first clinic appointment, if any, was subsequent to date of diagnosis) attended a specialist hepatitis clinic within 12 months of being diagnosed.
Seventeen per cent of those attending within 12 months had their first appointment within one month of HCV diagnosis; 13% had their first appointment within one week. The distribution of time to first appointment is shown separately for pre-Phase II and Phase II Action Plan eras in Fig. 2 .
Multifactorial logistic regression analysis ( Table 2) Separate tests for interaction (see Appendix, Table A1 ) between era and risk group and between era and source of referral (adjusting for all other covariates) indicated that era effects did not statistically differ for PWID compared with non-PWID (interaction OR = 0.7, 95% CI: 0.3 -1.4), for GP and prison referrals compared with hospital referrals (interaction ORs of 1.2, 95% CI: 0.8-1.6; 1.0, 95% CI: 0.5-1.9, respectively), but the era effect was significantly smaller for drug/counselling clinic referrals compared with hospital referrals (interaction OR = 0.5, 95% CI: 0.3-0.8). Regression analysis of the PWID subgroup only did not indicate an effect of era (OR = 0.9, 95% CI: 0.7-1.1). Subgroup analysis results for the three referral sources of interest were as follows: GP (OR = 1.4, 95% CI: 1.1-2.0), drug/counselling clinic (OR = 1.0, 95% CI: 0.6-1.7), and prison (OR = 0.4, 95% CI: 0.2-0.9), but should be interpreted with caution. There were 334 cases where the date of first clinic attendance was identical to the date of HCV diagnosis, of which 194 had a date of HCV diagnosis recorded as more than two months earlier on the Clinical database than the linked HCV diagnosis date. A sensitivity analysis was conducted to further explore this observation, by replacing the date of HCV diagnosis (from record-linkage) with the earlier date for these 194 cases. Logistic regression results were highly similar for both the linear temporal trend (OR = 1.06, approx. 95% CI:
1.05-1.08) and the effect of era (OR = 1.1, approx. 95% CI: 0.9-1.3). Table 3 shows the baseline characteristics of the study population for outcome (b), initiation on antiviral therapy among clinic attendees (n = 5,736; i.e., chronic HCV-infected patients with first clinic attendance in the period 1996-2009). The majority were males (71%), 67% were in the PWID risk group (81% of those with known risk group), and 43% had HCV genotype 2/3 (56% of those for whom genotype was known). The median age at start of follow-up was 35 years (IQR 29-42 years).
Initiation on antiviral therapy: demographic characteristics
Odds of initiation on antiviral therapy within 12 months of first clinic attendance
Sixteen per cent (919/5736) of patients were initiated on antiviral treatment within 12 months of their first attendance at a specialist clinic ( Table 3 ). Fig. 3 shows the cumulative probability of treatment initiation (within 12 months) for pre-Phase II and Phase II eras. In the regression analysis replacing period of first clinic with date of first clinic and era, the odds of treatment initiation, adjusted for the small linear temporal trend (OR = 1.05, approx. 95% CI: 1.02-1.08) and the other covariates, were significantly greater in the Phase II compared with the pre-Phase II Action Plan era (OR = 1.9, approx. 95% CI: 1. The supplementary interaction test between era and risk group, adjusting for all other covariates, indicated that the era effect for PWID or NK risk groups did not differ from the era effect for non-PWID (interaction OR=1.3, 95% CI: 0.8-2.1; OR=1.1, 95% CI: 0.6-1.8, respectively) (see Appendix, Table A1 ). Analysis of the prison referrals subgroup did not indicate a significant effect of era, after adjustment for temporal trend and other covariates (OR = 1.6, 95% CI: 0.5-5.1). with lower odds of first clinic appointment. For GP referrals only, we observed a Phase II era effect (1.4-fold increased odds), beyond the effect of a rising temporal trend in a subgroup analysis. The <1 OR observed for prison referrals is due to adjustment for the stronger (OR=1.24) temporal trend (Table A1 ) observed for this subgroup; despite the increased proportion of prison-referred diagnosees attending their first clinic appointment within 12 months in the Phase II era, this increase was small compared with the overall increase over the study period. Outcome (b), initiation on antiviral therapy within 12 months of first clinic attendance, was positively associated with being 40 years of age or older, and first clinic attendance in the Phase II era. Reduced odds of treatment initiation were found for PWID, for those with genotype 1 or unknown genotype compared with genotype 2/3, and for younger patients (20-29 years). The OR of 0.10 for unknown genotype reflects the fact that all patients who are to start treatment will generally be tested for genotype, but few will be tested in the absence of an intention to treat. Our analysis was not designed to ascertain the specific factors underlying the improvement in treatment rates associated with the implementation of the HCV Action Plan. Barriers to treatment initiation, for example due to ongoing injecting drug use, alcohol abuse, and a chaotic lifestyle, (14) may have improved during the Action Plan. Our results are consistent with injecting drug use as a barrier both to attending a specialist clinic following HCV diagnosis and to commencing antiviral therapy; for both outcome measures, the odds ratios associated with PWID or unknown risk activity categories compared with non-PWID were significantly lower than 1.0.
Random-effects logistic regression indicated that the odds of treatment initiation were
DISCUSSION
Evaluation of England
Analysis (a) focuses on evaluating the effect of Phase II initiation on first clinic attendance among persons newly diagnosed with HCV; however, health boards may have sought to boost attendance in other ways (e.g., re-connecting with persons lost to follow-up).
Similarly, analysis (b) focuses on patients newly attending clinics, and neglects efforts to reengage with past attendees.
The strengths of our study include a large study population, and comprehensive data available on important covariates. There are also a number of limitations. First, our deterministic record-linkage approach relied on the availability of sufficient identifiers; records with incomplete identifiers on the HCV Clinical database may be associated with poor attendance, rather than inadequate recording of information on the database. However the number of records with insufficient identifiers was small (n = 127). Failure to find valid links may also be associated with the HCV testing setting; for example, persons diagnosed in a GUM clinic will have limited identifiers on the HCV diagnosis database.
Second, our two outcome measures are not independent. Increasing the testing rates of patients who may already be showing early symptoms of liver damage could lead to an increased rate of referral to specialist clinics with the explicit goal of starting the patient on treatment; thus the observed improved treatment initiation rate in the Phase II era may be due, in part, to improved rates of diagnosis among those patients who are the most eligible for antiviral therapy. This is not an issue if one simply wishes to estimate rates of initiation on treatment; however, any improvements cannot easily be attributed to performance of a single aspect of the Action Plan. In addition, we do not yet have data covering the whole of Phase II of the Action Plan (i.e., May 2008 through March 2011); the effect sizes associated with the Phase II era may change with addition of further data.
Third, our method for distinguishing any intervention effect from a background increase over time fitted a linear trend over the entire study period; hence, the statistical test of the era regression coefficient, adjusting for temporal trend, is overly conservative. We had also considered using a variant of segmented regression analysis (15) , which was developed for linear regression modelling of time-series data. Although the approach appeared suitable for evaluating the effect of an intervention in the current data, as it fits separate regression lines to the periods before and after the time of intervention, we concluded that there were insufficient data in the second segment (the Phase II era) to allow meaningful interpretation.
This nation-level analysis reflects patient management pathways that exhibit substantial heterogeneity, in that the outcome measures for the various Health Boards differed at baseline, and specialist clinics responded to required changes associated with the HCV Action Plan at different rates; therefore, not all of the systems were functioning optimally during the Phase II period.
Finally, the populations for both analyses are subject to selection bias. For example, for outcome (b), the study population can be considered a 'prevalent cohort' (i.e., patients are chronically infected with HCV at the start of follow-up, but with variation in time since acquiring infection). Because patients with more advanced disease progression may be referred for treatment (see related point above), inclusion in the study population is associated with the outcome. Thus, treatment rates within 12 months of first appointment, although validly reflecting treatment rates in the study base (i.e., all patients attending specialist hepatitis care in Scotland), apply more to those patients with more advanced disease who may have a greater likelihood of being initiated on treatment relatively quickly.
In addition, HCV testing/diagnosis was not as widespread in the pre-Phase II compared with the Phase II period;(9) thus the earlier period will tend to include patients with more advanced disease compared with the Phase II period, with a consequent higher likelihood of being referred for specialist care soon after a positive diagnosis is made. Analyses that exclude a fixed period of observation following first specialist clinic appointment could be conducted to address the former issue; the latter issue must be taken into account when interpreting the current findings.
In summary, our analysis illustrates that the Hepatitis C Action Plan for Scotland has succeeded in increasing (over and above the temporal trend) the odds of initiating antiviral treatment among persons newly attending specialist clinics. The improvement observed over the study period in this key performance indicator is consistent with a positive impact of Scotland's Hepatitis C Action Plan on the management and care of chronically-infected individuals. Further monitoring and analysis is required to establish if there is any subsequent improvement in the odds of a first clinic attendance, and to confirm a sustained effect in the second outcome. This evaluation has substantial relevance to other countries looking to implement similar intervention plans. Table 2 . Results of logistic regression analyses, where outcome is defined as first attendance at a specialist clinic within the 12 month period following HCV diagnosis (n = 9,747).
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